Latin American Pharmaceutical Market Set To Grow To $126bn By 2022

08 August 2018
Pharma

Visiongain has launched a new pharma report Latin American Pharmaceutical Market Outlook 2018-2028: Brazil, Mexico, Venezuela, Argentina, Colombia, Chile, Rest of Latin America, Generics, OTC, Biosimilars, Originator Drugs

The Latin American pharmaceutical market accounts for 8% of the global pharmaceutical industry, and is one of its fastest growing markets. Macroeconomic conditions are hampering growth in the short term, but long-term growth is expected at high rates to 2028 and beyond. Many multinational companies have successfully gained entry to this market and are making large gains, but it remains a challenging environment for new entrants. The Latin American market requires strong local knowledge, as there are large differences between its constituent nations.

The lead analyst of this report said “The Latin American pharmaceutical market will continue to grow at a much higher rate than other, more mature markets for the next ten years. The reasons behind this growth will shift from expanding coverage to increasing incidence of diseases as the nations of Latin America develop economically. Governments across the region are looking to increase access to health care and an ageing population coupled with rises in the incidence of chronic diseases are driving demand.

Competition is high from both foreign and domestic companies, and national regulations can make investment difficult. Nevertheless, success in the Latin American pharmaceutical market is crucial for pharmaceutical companies seeking to maintain growth rates as developed markets stagnate.”

Leading companies featured in the report include Pfizer Inc., Bayer AG, Sanofi S.A, Novartis AG
And EMS SA.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever